A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients

Inclusion Criteria: * Patients who had symptoms of heartburn with a diagnosis of grade A to D reflux esophagitis according to the Los Angeles classification Exclusion Criteria: * Gastric or duodenal ulcers (excluding ulcer scars) * Concurrent presence of Barrett's esophagus * A history of a poor response to H2RA or PPI given in the recommended dose for 8 weeks * Other conditions considered by the attending physician to potentially affect the assessment of efficacy and safety